SiliconBeat

AP Pharma said today in a filing that it’s board was notified by two of its directors on Tuesday that they would not seek re-election to the board when their terms expire at the company’s next annual meeting, scheduled for May 27.

Peter Riepenhausen is stepping down after after 18 years on the company’s board, where he served on the audit and finance committee, compensation and stock option committee and nominating and governance committees. Also stepping down is the audit committee’s chairman, Arthur Taylor, who has served on the board since 2006.

The sole returning member of the audit committee will be Toby Rosenblatt, who, like Riepenhausen, also serves on the board’s other two standing committees. In fact, Rosenblatt, 70, who has been a director since 1983, appears to be the only returning member of any of the committees, based on information in the company’s proxy filed Thursday.

Missing from the filing is any of the usual boilerplate language testifying to the fact that neither Ripenhausen or Taylor are leaving because of any disagreement with the company or its policies, blah blah blah.

Which leads us to wonder if the February addition to the board of Kevin Tang, AP Pharma’s largest shareholder, has changed its chemistry in any significant way.